Broadleaf Capital Partners To Conduct Conference CallLAS VEGAS - Nov. 1, 2013 - PRLog -- Broadleaf Capital Partners, Inc. will conduct a conference call on Wednesday, November 6, 2013 at 10:00 AM pacific time. For those interested, the conference call number is: (712) 432-1699 -- then enter the access code: 702709 followed by the pound sign (#).
The principal purpose of the conference call will be to provide address questions concerning Broadleaf’s pending acquisition of Sustained Release, Inc. Broadleaf Capital Partners, Inc. and Sustained Release, Inc. (SRI) have agreed to terms and conditions under which Broadleaf will acquire Sustained Release, Inc. The agreement is scheduled to become effective on or before December 1, 2013. Mike King, President of Broadleaf, stated: “We have worked diligently to develop this opportunity to widen the scope of Broadleaf’s business activity and revenue base. Our goal is to enhance shareholder value and we believe that the Sustained Release acquisition will be positive in that regard.” Sustained Release has established a contract with Akina, Inc. relating to extended drug delivery systems. Over the last two years the pharmaceutical sector has experienced the “patent cliff” wherein they've had major drugs pass out of patent protection without being replaced by an equal amount of newly approved and protected drugs. One of the many advantages of Akina’s patent protected technology is that it provides pharmaceutical companies with the ability to dynamically compete with generic versions of their drugs. Akina, Inc. is a research and development company known for developing unique methods for delivering medications. It was founded in 2001 by Kinam Park, Showalter Distinguished Professor of Biomedical Engineering and Professor of Pharmaceutics at Purdue University. Akina Is a pioneer in the development of the long-term release microparticle formulations, also referenced as “Sustained Release Formulations,” The Akina microparticles are programmable in release kinetics and ideal for release of active pharmaceutical ingredients for terms ranging from a few weeks to several months. They are inexpensive to produce, readily scalable for mass production, and offer a wide range of clinical applications. Examples of current microparticle formulations under development at Akina address specific conditions such as macular degeneration, glaucoma, periodontal disease, and inflammation. Akina’s hydrogel template method is highly unique in that the process does not include oil/water emulsion, and thus it allows controlled manipulation of the drug/polymer formulation which has not been possible by other methods. About Broadleaf Capital Partners Broadleaf Capital Partners Inc. Inc. actively identifies and reviews unique and proprietary technologies for investment consideration. Broadleaf seeks such technologies held by emerging or early stage, small to medium-size companies in various fields of business to arrange for capital and provide management support. Our goal is to provide our stockholders capital appreciation and a solid dividend yield. Learn more about Broadleaf at: www.bdlfpartner .com This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," Contacts Princeton Research, Inc., Las Vegas Mike King, 702-650-3000 mike@princetonresearch.com Broadleaf Capital Partners Inc., Las Vegas End
Page Updated Last on: Nov 01, 2013
|
Account Phone Number